Results 21 to 30 of about 199,032 (289)
Immune Checkpoint Inhibitor Toxicities [PDF]
Mayo Clinic Proceedings, 2019 Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been
Julian A. Marin-Acevedo +2 more
openaire +2 more sources
Immune Checkpoint Inhibitors in Melanoma [PDF]
Melanoma Management, 2015 The potential to harness the power of the immune system and effectively treat patients with metastatic melanoma is finally being realized with the advent of immune checkpoint inhibitors. These new therapies herald a new era in the treatment of melanoma with the potential to produce very durable responses and possible cure for a subset of patients ...
Adam J, Cooper +2 more
openaire +2 more sources
Journal for ImmunoTherapy of Cancer, 2019 Background In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint inhibitors.
Rayan Alsuwaigh +4 more
doaj +1 more source
Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition
JEADV Clinical Practice, 2023 The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer +4 more
doaj +1 more source
Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer
Zhongliu Fangzhi Yanjiu, 2019 With the gradually in-depth research of immune checkpoint, the checkpoint inhibitors, such as programmed death-1(PD-1) inhibitors, programmed death–ligand 1(PD-L1) inhibitors and cytotoxic T lymphocyte-associated protein-4(CTLA-4) inhibitors, had made ...
LI Xiangmin, FAN Zaiwen
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2020 Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/
Minjeong Yeon +3 more
doaj +1 more source
Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
Zhongliu Fangzhi Yanjiu, 2021 Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers.
YU Lin +3 more
doaj +1 more source
Cancer Biology & Medicine, 2015 Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor ...
Jennifer Kleponis +2 more
doaj +1 more source
Electrocardiographic features of immune checkpoint inhibitor-associated myocarditis. [PDF]
, 2022 Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events including myocarditis, whilst improving cancer-related outcomes.
Song, Wenhua +10 more
core +1 more source
Journal of Immunology Research, 2020 Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis +4 more
doaj +1 more source